Frontlight ResearchEarly access
Active, not recruitingPhase 1
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Key facts
- Who runs it
- Arrowhead Pharmaceuticals
- Where
- Australia, Canada, France, Germany, Italy, New Zealand, Spain, and Taiwan22 sites in 8 countriesChoose a country to see its sites
- Trial code
- NCT06672445
- EU 2024-514763-25-01
- U1111-1308-5875
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 39 people enrolled
- Started
- 17 Dec 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ARO-ATXN2 Injection
- Placebo
- Record updated
- 29 June 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Non-pregnant, non-lactating
- Diagnosis of symptomatic SCA2 and ≥33 CAG repeats in the ATXN2 gene based on source verifiable medical records or genetic testing at Screening
- Scale of Assessment and Rating of Ataxia (SARA) score ≤14
- Subjects of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Subjects must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later
Who cannot take part
- History of having received stem cell therapy
- Uncontrolled hypertension (blood pressure >160/100 mmHg)
- Clinically significant cardiac, liver, or renal disease
- Human immunodeficiency virus (HIV) infection (seropositive at Screening)
- Seropositive for hepatitis B (HBV) or hepatitis C (HCV) at Screening
- Any contraindications to lumbar puncture, including INR >1.4, platelet count <100,000, and use of anticoagulant or antiplatelet medications that cannot be safely interrupted
- Intellectual disability or significant behavioral neuropsychiatric manifestation
- Presence of an implanted shunt for drainage of CSF or an implanted central nervous system (CNS) catheter; Note: Additional inclusion/exclusion criteria may apply per protocol
Where is this trial?
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.
The 2 groups in the trial
- ARO-ATXN2Treatment being tested
ARO-ATXN2 Injection
Treatment: ARO-ATXN2 Injection
- PlaceboPlacebo, for comparison
(0.9% NaCl)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2
- Record updated
- 29 June 2026